Table 2 Antimicrobial activity as the zone of inhibition ZOI (mm) of prepared samples against some pathogenic bacteria and yeast.

From: Synthesis and applicability of reduced graphene oxide/porphyrin nanocomposite as photocatalyst for waste water treatment and medical applications

Test organism

Porphyrin

rGO

rGO-P composite

E/Nystatin

 

ZOI (mm)

ZOI (mm)

ZOI (mm)

ZOI (mm)

S. aureus (ATCC 25,923)

9.b5 ± 0.14

14.a4 ± 0.23

22.b1 ± 0.24

22.5a ± 0.29

E. coli (ATCC 25,922)

8.c6 ± 0.17

13.b4 ± 0.20

18.c4 ± 0.32

18.7b ± 0.24

Enterococcus faecalis (ATCC 29,212)

9.b3 ± 0.24

12.c4 ± 0.17

b21.8 ± 0.72

6.5d ± 0.29

Shigella sonnei (ATCC 29,531)

7.d5 ± 0.17

10.e5 ± 0.18

15.d2 ± 0.33

−ve

Candida albicans (ATCC 14,053)

12.a4 ± 0.20

11.d4 ± 0.14

24.a3 ± 0.17

12.6c ± 0.18

  1. *Values are means ± SD (n = 3). Data within the groups are analyzed utilizing one-way analysis of variance (ANOVA) accompanied bya, b, c, d, e Duncan's multiple range test (DMRT).
  2. *rGO = reduced graphene oxide and rGO-P = reduced graphene oxide loaded porphyrin, −ve = no ZOI had been measured, E = Erythromycin; 20 μg/ml antibacterial standard. Nystatin 10 μg/ml antifungal standard.
  3. LSD Least significant differences.